evans blue has been researched along with felodipine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Rydén, L; Shimizu, M; Sjöquist, PO; Wang, QD | 1 |
2 other study(ies) available for evans blue and felodipine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combination of a calcium antagonist, a lipid-peroxidation inhibitor, and an angiotensin AT1-receptor antagonist provides additive myocardial infarct size-limiting effect in pigs.
Topics: Anesthesia; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Coronary Disease; Drug Synergism; Drug Therapy, Combination; Evans Blue; Felodipine; Female; Hemodynamics; Indoles; Lipid Peroxidation; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion; Myocardial Reperfusion Injury; Perfusion; Random Allocation; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Swine; Terphenyl Compounds; Tetrazoles | 1999 |